Cargando…
Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib
Recent efforts to personalize treatment with platinum-based chemotherapy and PARP inhibitors have produced promising results in homologous recombinant deficient (HRD) metastatic pancreatic cancer (MPC). However, new strategies are necessary to overcome resistance. The below case series documents pat...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687686/ https://www.ncbi.nlm.nih.gov/pubmed/36359225 http://dx.doi.org/10.3390/biomedicines10112705 |
_version_ | 1784836070831030272 |
---|---|
author | Botrus, Gehan Roe, Denise Jameson, Gayle S. Junior, Pedro Luiz Serrano Uson Korn, Ronald Lee Caldwell, Lana Bargenquast, Taylor Miller, Max Borazanci, Erkut Hasan |
author_facet | Botrus, Gehan Roe, Denise Jameson, Gayle S. Junior, Pedro Luiz Serrano Uson Korn, Ronald Lee Caldwell, Lana Bargenquast, Taylor Miller, Max Borazanci, Erkut Hasan |
author_sort | Botrus, Gehan |
collection | PubMed |
description | Recent efforts to personalize treatment with platinum-based chemotherapy and PARP inhibitors have produced promising results in homologous recombinant deficient (HRD) metastatic pancreatic cancer (MPC). However, new strategies are necessary to overcome resistance. The below case series documents patients treated at the HonorHealth Research Institute with a diagnosis of HRD MPC who received Mitomycin C (MMC) treatment from January 2013 until July 2018. Five HRD MPC patients treated with MMC were evaluated. All patients received at least one course of treatment. Mean age at MMC treatment initiation was 58 years. There were 3 females and 2 males. All patients had tumors that progressed on platinum-based chemotherapy, four patients had previous exposure to Olaparib. The median PFS was 10.1 months, and the median OS was 12.3 months. Responses were observed only in patients harboring BRCA2 mutations, no response was observed in the PALB2 mutation carrier. MMC in this heavily previously treated PC was safe, with overall manageable grade 2 gastrointestinal toxicities including nausea and vomiting, and G3 hematological toxicities including anemia and thrombocytopenia. Pancreatic cancer patients with HRD may benefit from MMC treatment. Further clinical investigation of MMC in pancreatic cancer is warranted. |
format | Online Article Text |
id | pubmed-9687686 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96876862022-11-25 Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib Botrus, Gehan Roe, Denise Jameson, Gayle S. Junior, Pedro Luiz Serrano Uson Korn, Ronald Lee Caldwell, Lana Bargenquast, Taylor Miller, Max Borazanci, Erkut Hasan Biomedicines Article Recent efforts to personalize treatment with platinum-based chemotherapy and PARP inhibitors have produced promising results in homologous recombinant deficient (HRD) metastatic pancreatic cancer (MPC). However, new strategies are necessary to overcome resistance. The below case series documents patients treated at the HonorHealth Research Institute with a diagnosis of HRD MPC who received Mitomycin C (MMC) treatment from January 2013 until July 2018. Five HRD MPC patients treated with MMC were evaluated. All patients received at least one course of treatment. Mean age at MMC treatment initiation was 58 years. There were 3 females and 2 males. All patients had tumors that progressed on platinum-based chemotherapy, four patients had previous exposure to Olaparib. The median PFS was 10.1 months, and the median OS was 12.3 months. Responses were observed only in patients harboring BRCA2 mutations, no response was observed in the PALB2 mutation carrier. MMC in this heavily previously treated PC was safe, with overall manageable grade 2 gastrointestinal toxicities including nausea and vomiting, and G3 hematological toxicities including anemia and thrombocytopenia. Pancreatic cancer patients with HRD may benefit from MMC treatment. Further clinical investigation of MMC in pancreatic cancer is warranted. MDPI 2022-10-26 /pmc/articles/PMC9687686/ /pubmed/36359225 http://dx.doi.org/10.3390/biomedicines10112705 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Botrus, Gehan Roe, Denise Jameson, Gayle S. Junior, Pedro Luiz Serrano Uson Korn, Ronald Lee Caldwell, Lana Bargenquast, Taylor Miller, Max Borazanci, Erkut Hasan Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib |
title | Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib |
title_full | Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib |
title_fullStr | Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib |
title_full_unstemmed | Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib |
title_short | Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib |
title_sort | mitomycin c in homologous recombination deficient metastatic pancreatic cancer after disease progression on platinum-based chemotherapy and olaparib |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687686/ https://www.ncbi.nlm.nih.gov/pubmed/36359225 http://dx.doi.org/10.3390/biomedicines10112705 |
work_keys_str_mv | AT botrusgehan mitomycincinhomologousrecombinationdeficientmetastaticpancreaticcancerafterdiseaseprogressiononplatinumbasedchemotherapyandolaparib AT roedenise mitomycincinhomologousrecombinationdeficientmetastaticpancreaticcancerafterdiseaseprogressiononplatinumbasedchemotherapyandolaparib AT jamesongayles mitomycincinhomologousrecombinationdeficientmetastaticpancreaticcancerafterdiseaseprogressiononplatinumbasedchemotherapyandolaparib AT juniorpedroluizserranouson mitomycincinhomologousrecombinationdeficientmetastaticpancreaticcancerafterdiseaseprogressiononplatinumbasedchemotherapyandolaparib AT kornronaldlee mitomycincinhomologousrecombinationdeficientmetastaticpancreaticcancerafterdiseaseprogressiononplatinumbasedchemotherapyandolaparib AT caldwelllana mitomycincinhomologousrecombinationdeficientmetastaticpancreaticcancerafterdiseaseprogressiononplatinumbasedchemotherapyandolaparib AT bargenquasttaylor mitomycincinhomologousrecombinationdeficientmetastaticpancreaticcancerafterdiseaseprogressiononplatinumbasedchemotherapyandolaparib AT millermax mitomycincinhomologousrecombinationdeficientmetastaticpancreaticcancerafterdiseaseprogressiononplatinumbasedchemotherapyandolaparib AT borazancierkuthasan mitomycincinhomologousrecombinationdeficientmetastaticpancreaticcancerafterdiseaseprogressiononplatinumbasedchemotherapyandolaparib |